Evaluation of Approved and Investigational Contact Lenses

NCT03228212 | Completed Results FDA Device

• 1 other identifier: CR-5960
• Study Type: interventional
• Target: 133
• Locations: 1 country
• Sites: 5

Brief Summary

This study is a randomized, 5-visit, partial subject masked, 2x3 bilateral crossover, dispensing clinical trial. During the study, each test article will be worn in a daily wear modality for at least 6 hours per day and 5 days per week for approximately 2 weeks each. The subject will wear either the Test or Control article twice and the other study article once. The primary objective of this study is to demonstrate that the Test lens works as well, if not better compared to the Control lens with respect to CLUE (Contact Lens User Experience) comfort, Slit Lamp findings, and Distance Monocular logMAR Visual Acuity. This study will also aim to show acceptable lens fit for subjects wearing the Test lens.

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (4)

• Overall Comfort

  Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The average comfort score from the 3 study periods was reported.

  2-Week Follow-up

• Distance Monocular LogMAR Visual Acuity

  Distance Monocular LogMAR visual acuity was assessed at 4 meters using an ETDRS chart at the 2-week follow-up for each subject eye during each of the three study periods. The average visual acuity for each lens type from the 3 study periods was reported.

  2-Week Follow-up

• Contact Lens Fitting Acceptance Rate

  Contact lens fitting acceptance was assessed for each subject eye using a biomicroscope at post lens insertion and the 2-week follow-up. Lens fit was a binary variable where acceptable lens fit=1 and unacceptable lens fit=0. The proportion of eyes with acceptable lens fit was reported for each lens. The lens fit acceptance rate for both post lens fitting at the 2-week follow-up was reported for each lens type.

  Up to 2-Week Follow-up

• Number of Grade 3 or Higher Slit Lamp Findings

  Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). This was performed on each subject eye at every study visit (baseline, unscheduled visits and 2-week follow-up). The data was then dichotomized into two groups. Those with grade 3 or higher and those with grade 2 or lower. The number of SLF with grade 3 or higher by lens was reported.

  Up to 2-Week Follow-up

Secondary Outcomes (2)

• Overall Quality of Vision

  2-Week Follow-up

• Overall Handling

  2-Week Follow-up

Study Arms (2)

TEST/CONTROL/CONTROL

EXPERIMENTAL

Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)

Device: CONTROL; Device: TEST

CONTROL/TEST/TEST

EXPERIMENTAL

Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)

Device: CONTROL; Device: TEST

Interventions

CONTROL DEVICE

ACUVUE OASYS

CONTROL/TEST/TEST; TEST/CONTROL/CONTROL

TEST DEVICE

senofilcon A with new UV blocker

CONTROL/TEST/TEST; TEST/CONTROL/CONTROL

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• The subject must read and sign the Informed Consent form.
• The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Healthy adult males or females age ≥18 and ≤49 years of age with signed informed consent. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them.
• The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 6.00 Diopter (D).
• The subject's refractive cylinder must be ≤ 1.00D in each eye.
• The subject must have visual acuity best correctable to 20/25+3 or better for each eye.
• Subjects must own a wearable pair of spectacles.
• The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of Daily Wear per day, at least 5 days per week, for a minimum of 1 month prior to the study) and willing to wear the study lenses on a similar basis.
• Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week
• The subject must have normal eyes (i.e., no ocular medications or infections of any type).

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
• Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
• Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral (e.g., Chlor-Trimeton, and Benadryl) and ophthalmic antihistamines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol), systemic steroids, and any prescribed or over the counter (OTC) ocular medication.
• Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion.
• Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), LASIK, etc.).
• Any Grade 3 or greater slit lamp findings (e.g.., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
• Any known hypersensitivity or allergic reaction to Optifree®PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution
• Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study.
• Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
• Toric, extended wear, monovision or multi-focal contact lens correction.
• Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
• Participation in clinical trials involving the Test lens within 3 months prior to study enrollment.
• History of binocular vision abnormality or strabismus.
• Employee, relative or friends of employees of any ophthalmic company, or investigational clinic (e.g., Investigator, Coordinator, Technician).

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (5)

Dr. James Weber & Associates, PA

Jacksonville, Florida, 32205, United States

Location

Vue Optical Boutique

Jacksonville, Florida, 32250, United States

Location

VisionCare Associates

East Lansing, Michigan, 48823, United States

Location

Pickens Family Eye Care

Pickens, South Carolina, 29671, United States

Location

William J. Bogus, OD

Salt Lake City, Utah, 84106, United States

Location

Results Point of Contact

• Title: John Buch -SENIOR PRINCIPAL RESEARCH OPTOMETRIST
• Organization: Johnson & Johnson Vision Care Inc.

JBUCH@its.jnj.com

904 443-1707

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2017
• First Posted: July 24, 2017
• Study Start: July 14, 2017
• Primary Completion: September 18, 2017
• Study Completion: September 18, 2017
• Last Updated: December 13, 2018
• Results First Posted: December 13, 2018

Record last verified: 2018-12

Locations

US (5)